The 63D3.rMAb is a recombinant monoclonal antibody that specifically recognizes human CD14 which is also known as Monocyte differentiation antigen CD14, Myeloid cell-specific leucine-rich glycoprotein, or LPS Receptor (LPS-R). CD14 is expressed as an ~55 kDa glycophosphatidylinositol (GPI)-linked cell surface glycoprotein. CD14 is highly expressed on most mature monocytes and macrophages, and at lower levels on neutrophils. CD14 is also expressed on some dendritic cells (DC) and Langerhans cells. CD14 binds to bacterial cell wall components including lipopolysaccharide (LPS) bound to lipopolysaccharide-binding protein (LBP). CD14 serves as a co-receptor for certain signaling Toll-like receptors (TLRs) for the cellular detection and response to LPS as well as other pathogen-associated molecular patterns (PAMPs). Ligand-bound CD14 plays a role in stimulating various myeloid cells to produce pro-inflammatory cytokines and mediators and to upregulate the expression of cell surface adhesion molecules. Soluble forms of CD14 (sCD14) are reportedly released by cells into the blood or other bodily fluids. Soluble CD14 can regulate cellular responses to LPS and confer LPS-responsiveness to cells that do not ordinarily express CD14.
The antibody was conjugated to BD Horizon™ BUV805 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348 nm and an acceptor dye with an Em Max at 805 nm. BD Horizon Brilliant BUV805 can be excited by the ultraviolet laser (355 nm) and detected with a 820/60 filter and a 770LP.